OVID logo

Ovid Therapeutics (OVID) Company Overview

Profile

Full Name:

Ovid Therapeutics Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 5, 2017

Indexes:

Not included

Description:

Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological disorders. They aim to improve the lives of patients through innovative therapies, particularly for conditions like epilepsy and other central nervous system diseases. Their research combines science and patient needs to create effective solutions.

Events Calendar

Earnings

Next earnings date:

Mar 7, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 8, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 29, 25 Oppenheimer
Outperform
Dec 4, 24 HC Wainwright & Co.
Buy
Sep 30, 24 HC Wainwright & Co.
Buy
Aug 19, 24 HC Wainwright & Co.
Buy
Jul 26, 24 HC Wainwright & Co.
Buy
Jul 2, 24 HC Wainwright & Co.
Buy
Jun 18, 24 HC Wainwright & Co.
Buy
Jun 18, 24 Citigroup
Neutral
Jun 18, 24 BTIG
Buy
Jun 18, 24 B. Riley Securities
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
OVID
zacks.comNovember 12, 2024

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
OVID
zacks.comAugust 20, 2024

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
OVID
accesswire.comAugust 18, 2024

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
OVID
accesswire.comAugust 17, 2024

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
OVID
accesswire.comAugust 16, 2024

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
OVID
accesswire.comAugust 14, 2024

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
OVID
globenewswire.comAugust 13, 2024

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
OVID
accesswire.comAugust 12, 2024

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
OVID
globenewswire.comAugust 3, 2024

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
OVID
prnewswire.comAugust 1, 2024

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

FAQ

  • What is the ticker symbol for Ovid Therapeutics?
  • Does Ovid Therapeutics pay dividends?
  • What sector is Ovid Therapeutics in?
  • What industry is Ovid Therapeutics in?
  • What country is Ovid Therapeutics based in?
  • When did Ovid Therapeutics go public?
  • Is Ovid Therapeutics in the S&P 500?
  • Is Ovid Therapeutics in the NASDAQ 100?
  • Is Ovid Therapeutics in the Dow Jones?
  • When was Ovid Therapeutics's last earnings report?
  • When does Ovid Therapeutics report earnings?
  • Should I buy Ovid Therapeutics stock now?

What is the ticker symbol for Ovid Therapeutics?

The ticker symbol for Ovid Therapeutics is NASDAQ:OVID

Does Ovid Therapeutics pay dividends?

No, Ovid Therapeutics does not pay dividends

What sector is Ovid Therapeutics in?

Ovid Therapeutics is in the Healthcare sector

What industry is Ovid Therapeutics in?

Ovid Therapeutics is in the Biotechnology industry

What country is Ovid Therapeutics based in?

Ovid Therapeutics is headquartered in United States

When did Ovid Therapeutics go public?

Ovid Therapeutics's initial public offering (IPO) was on May 5, 2017

Is Ovid Therapeutics in the S&P 500?

No, Ovid Therapeutics is not included in the S&P 500 index

Is Ovid Therapeutics in the NASDAQ 100?

No, Ovid Therapeutics is not included in the NASDAQ 100 index

Is Ovid Therapeutics in the Dow Jones?

No, Ovid Therapeutics is not included in the Dow Jones index

When was Ovid Therapeutics's last earnings report?

Ovid Therapeutics's most recent earnings report was on Nov 12, 2024

When does Ovid Therapeutics report earnings?

The next expected earnings date for Ovid Therapeutics is Mar 7, 2025

Should I buy Ovid Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions